ArticleScientific reports2026
AI-driven framework for accurate detection of Alzheimer's disease in EEG.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's Disease (AD) is a rapidly growing neurodegenerative disorder that severely impairs cognitive function, particularly among older adults. Early detection is critical for timely intervention and effective management. While electroencephalography (EEG) provides a non-invasive, cost-effective tool with high temporal resolution for diagnosing Alzheimer's Disease (AD), traditional EEG-based approaches often struggle to extract informative features accurately from complex brain signals, thus limiting their diagnostic performance. This study addresses these challenges by proposing a novel artificial intelligence-based framework that integrates feature fusion with a Convolutional Long Short-Term Memory (Conv-LSTM) architecture. The model combines spectral features and deep learning-derived representations into a unified feature set, which is then processed by the LSTM network to capture both spatial and temporal patterns associated with AD. The proposed method achieves a classification accuracy of 99.8%, outperforming existing techniques and demonstrating its effectiveness in distinguishing between multiple stages of AD. Experimental results confirm the superiority of the fusion-based approach in learning high-level, discriminative features from EEG signals. This research represents a significant advancement in EEG-based Alzheimer's disease (AD) detection, with strong potential for enhancing early diagnostic systems. It supports the development of intelligent, scalable clinical tools for dementia screening and contributes to the broader effort to integrate AI into the diagnosis of neurodegenerative diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.